Endogenous Modulation of Cochlear Injury

耳蜗损伤的内源性调节

• 批准号: 9231405
• 负责人: LEONARD P RYBAK
• 金额: $ 30.98万
• 依托单位: SOUTHERN ILLINOIS UNIVERSITY SCH OF MED
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-07-01 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9231405
• 关键词: Affect; Afferent Neurons; Agonist; Animal Experiments; Anti-Inflammatory Agents; Anti-inflammatory; Apoptosis; Apoptotic; Bilateral; Biological Assay; Breast; CNR1 gene; CNR2 gene; Cancer Patient; Cannabinoids; Capsaicin; Capsicum; Cells; Chemotherapy-Oncologic Procedure; Child; Cisplatin; Clinical; Cochlea; Data; Dose; Ear; Evoked Potentials, Auditory, Brain Stem; Future; Gene Expression Profiling; Genes; Head and Neck Cancer; Human; In Vitro; Inflammatory; Inflammatory Response; Injectable; Injection of therapeutic agent; Injury; Interleukin-1 beta; Laboratories; Labyrinth; Link; Malignant Neoplasms; Mediating; Molecular; Oral; Oral Administration; Ovarian; Oxidative Stress; Pathway interactions; Pharmacotherapy; Phosphorylation; Preparation; Protein p53; Proteins; RNA; Rattus; Reporting; Research; Research Proposals; Resistance; Role; SCID Mice; STAT protein; STAT1 gene; STAT3 gene; Scanning Electron Microscopy; Social Development; Speech Development; TNF gene; TP53 gene; TRPV1 gene; TdT-Mediated dUTP Nick End Labeling Assay; Testing; Time; Tissues; Transcript; Tumor Cell Line; Tumor Suppressor Proteins; Universities; Up-Regulation; Western Blotting; analog; cancer cell; cancer therapy; cannabinoid receptor; cognitive development; cytokine; differential expression; experimental study; functional genomics; hearing impairment; immunocytochemistry; in vivo; interest; novel; novel therapeutics; ototoxicity; preconditioning; prevent; public health relevance; receptor; receptor expression; relating to nervous system; tumor

DESCRIPTION (provided by applicant): Cisplatin is a critical component of current chemotherapy regimens. Unfortunately, cisplatin frequently causes ototoxicity that is bilateral and irreversible. This is particularly challenging in young children in whom hearing loss severely hampers speech, cognitive and social development. Thus, there is an urgent need for new drugs to reduce cisplatin ototoxicity. Recent studies from our laboratory have shown that a single transtympanic injection of capsaicin (TRPV1 agonist) produced transient hearing loss and temporary increases in inflammatory cytokines. Surprisingly, pretreatment with transtympanic capsaicin alleviated cisplatin ototoxicity. Preliminary data show that oral capsaicin also reduces cisplatin-induced auditory brain stem response (ABER) threshold shifts. Our in vitro studies suggest that capsaicin's "preconditioning" effect results from transient STAT1 up-regulation. Activation of STAT1 by capsaicin may modify or sequester STAT1, preventing its interaction with p53 when cochlear cells are subsequently challenged by cisplatin. Alternatively, capsaicin could activate STAT1 (i.e. increase its phosphorylation) differently from cisplatin. Capsaicin could also activate cytoprotective STAT proteins (such as STAT3). Capsaicin can also increase cannabinoid (CB) expression in the cochlea, which can be cytoprotective. Preliminary experiments in UB/OC1 cells show that capsaicin up-regulates CB receptors in these cells. Experiments in aim1 should confirm the efficacy of oral capsaicin against cisplatin ototoxicity and the subsequent 3 aims will elucidate mechanisms of protection. Aim 2 will determine the molecular basis of capsaicin-mediated protection against cisplatin ototoxicity. The hypothesis is that capsaicin activates STAT1 (by mediating Ser727 and Tyr701 phosphorylation) which sequesters (or down-regulates) it, thereby decreasing the availability of STAT1 accessible for activation by cisplatin. Aim 3 will test the hypothesis that capsaicin-mediated protection against cisplatin ototoxicity by activation, or increasing the expression, of CB receptors in the cochlea. CB activation reduces cisplatin ototoxicity in vitro and has demonstrated anti-inflammatory and neuroprotective effects in numerous reports. Aim 4 will test the hypothesis that Gene Array will demonstrate changes in genes of interest in the cochlea of rats treated with capsaicin, cisplatin and cisplatin plus capsaicin. Aim 5 will determine whether capsaicin interferes with or actually enhances the antitumor efficacy of cisplatin. This research will offer great promise to provide novel protective oral treatments to ameliorate cisplatin ototoxicity.

描述（由申请人提供）：顺铂是当前化疗方案的关键组成部分。不幸的是，顺铂经常引起双侧和不可逆的耳毒性。这对于听力损失严重阻碍言语、认知和社会发展的幼儿来说尤其具有挑战性。因此，迫切需要新的药物来减少顺铂的耳毒性。我们实验室最近的研究表明，单次经鼓膜注射辣椒素（TRPV 1激动剂）可导致短暂性听力损失和炎性细胞因子的暂时性增加。令人惊讶的是，经鼓膜辣椒素预处理减轻了顺铂的耳毒性。初步数据显示，口服辣椒素也减少顺铂诱导的听觉脑干反应（ABER）阈值偏移。我们的体外研究表明，辣椒素的“预处理”效果的结果从短暂的STAT 1上调。辣椒素激活STAT 1可能会改变或隔离STAT 1，防止其与p53的相互作用时，耳蜗细胞随后受到顺铂的挑战。或者，辣椒素可以激活STAT 1（即增加其磷酸化）不同于顺铂。辣椒素还可以激活细胞保护性STAT蛋白（如STAT 3）。辣椒素还可以增加耳蜗中大麻素（CB）的表达，这可以是细胞保护性的。在UB/OC 1细胞中的初步实验表明，辣椒素上调这些细胞中的CB受体。aim 1的实验应证实口服辣椒素对顺铂耳毒性的有效性，随后的3个目标将阐明保护机制。目的2：探讨辣椒素介导的顺铂耳毒性保护作用的分子基础。该假说是辣椒素激活STAT 1（通过介导Ser 727和Tyr 701磷酸化），从而隔离（或下调）它，从而降低顺铂激活STAT 1的可用性。目的3将检验辣椒素通过激活或增加耳蜗中CB受体的表达介导的对顺铂耳毒性的保护的假设。CB激活在体外降低顺铂耳毒性，并在许多报告中证明了抗炎和神经保护作用。目的4将检验基因阵列将证明用辣椒素、顺铂和顺铂加辣椒素处理的大鼠耳蜗中感兴趣的基因的变化的假设。目的5将确定辣椒素是否干扰或实际上增强顺铂的抗肿瘤疗效。这项研究将提供很大的希望，提供新的保护性口服治疗，以改善顺铂耳毒性。